Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

26/07/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.93 USD

Average target price

53.19 USD

Spread / Average Target

+26.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-18.28%	85B
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 22/06/2024 am IST			5-day change	1st Jan Change
41.93 ^USD	+2.17%		+1.77%	-18.28%

22/06	Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	CI
21/06	Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	MT

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06	CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	22/06	MT
US FDA approves Bristol Myers' colorectal cancer therapy	21/06	RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06	MT
Bristol Myers: application validated for subcutaneous Opdivo	21/06	CF
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06	CI
Bristol Myers: ex-CEO of Agilent joins Board of Directors	19/06	CF
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	19/06	CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06	MT
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	18/06	MT
Bristol Myers: Board declares dividend	18/06	CF
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	18/06	CI
Bristol Myers: FDA approval for treatment	14/06	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	14/06	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	14/06	DJ
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	14/06	CI
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12/06	MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12/06	MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12/06	CI
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM	11/06
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10/06	MT
Geron shares surge after U.S. FDA approves blood disorder drug	07/06	RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06	CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	04/06	MT